Pituitary/growth disorders
NEWS
Some children with congenital adrenal hyperplasia (CAH) could benefit from treatment with the aromatase inhibitor anastrozole to optimise their growth potential, US researchers suggest.
Once daily oral treatment with infigratinib has a tolerable side effect profile and a significant positive benefit on both annualised height velocity and upper-to-lower body segment ratio in children with achondroplasia, indicates research published in The New England Journal of Medicine.
Researchers have identified novel pathogenic variants that may account for approximately 9% of children with Silver–Russell syndrome who have not previously had a molecular diagnosis and aid understanding of the relationships between genotype and phenotype.
One-year findings from the REAL5 trial show a continued growth response with use of long-acting human growth hormone treatment with somapacitan at a dose of 0.24 mg/kg per week in children born small for gestational age.
In depth
In our latest expert review, Afiya Andrews outlines the broad phenotypic spectrum of classical and non-classical growth hormone insensitivity disorders in children.
We are excited to welcome you to the Insights into MAnaging Growth for Endocrine nurses (IMAGE) June 2025 Meeting, organised by Springer Healthcare IME. This event will take place on 5–6 June 2025 in the vibrant city of Lisbon in Portugal.
A 12-year-old boy with a diagnosis of Carney Complex (CC) has accelerated growth. How does the endocrinologist manage this patient?
The Insights into MAnaging Growth for Endocrine nurses (IMAGE) March 2024 Meeting, organised by Springer Healthcare IME, provides high-quality, practical clinical training for nurses involved in paediatric endocrinology practice.
